# Atezolizumab

Source: https://onco.cc/drugs/atezolizumab/  
OnCo record `atezolizumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A PD-L1 blocker used in lung, liver, and bladder cancer. In 2026 it became the first drug approved based on a blood test showing leftover cancer after bladder surgery.

## Summary

Approvals in NSCLC (including adjuvant, IMpower010), SCLC (first-line with chemotherapy, IMpower133), HCC (with bevacizumab, IMbrave150), melanoma (with cobimetinib/vemurafenib), alveolar soft-part sarcoma, and Q2 2026 adjuvant ctDNA-positive muscle-invasive bladder cancer (IMvigor011), the first ctDNA-guided approval. Its TNBC indication (IMpassion130) was withdrawn in the US in 2021.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-04
- Brand: Tecentriq / Tecentriq Hybreza (SC)
- Modality: Monoclonal antibody (anti-PD-L1)
- Mechanism: Fc-engineered humanised IgG1 anti-PD-L1.
- Approvals: US 2016: Urothelial carcinoma (later withdrawn); NSCLC; US 2026: Adjuvant muscle-invasive bladder cancer, ctDNA-positive after cystectomy; EU 2019: Unresectable locally advanced or metastatic TNBC with PD-L1 expression of 1 percent or more (SP142 immune cells), with nab-paclitaxel, no prior chemotherapy for metastatic disease (IMpassion130); the indication remains in the EU product information on 24 September 2026; UK 2020: Triple-negative unresectable locally advanced or metastatic breast cancer with PD-L1 of 1 percent or more, with nab-paclitaxel, untreated for metastatic disease; NICE TA639 (1 July 2020) recommends within the marketing authorisation with a commercial arrangement; England (NICE) 2018: Locally advanced or metastatic non-small-cell lung cancer after chemotherapy; England (NICE) 2019: Metastatic non-squamous non-small-cell lung cancer, with bevacizumab, carboplatin and paclitaxel; England (NICE) 2020: Untreated extensive-stage small-cell lung cancer, with carboplatin and etoposide; England (NICE) 2021: Untreated metastatic non-small-cell lung cancer with PD-L1 on at least 50 percent of tumour cells or 10 percent of tumour-infiltrating immune cells and no EGFR or ALK alteration; England (NICE) 2025: Adjuvant treatment of resected non-small-cell lung cancer after platinum chemotherapy, where PD-L1 is on 50 percent or more of tumour cells and the tumour is not EGFR-mutant or ALK-positive
- Dosing: IV infusion (subcutaneous Tecentriq Hybreza available); 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks
- Toxicity (grade 3+): Hypothyroidism (immune-mediated) 0.2%; Pneumonitis (immune-mediated) 0.8%; Hepatitis (immune-mediated) 0.7%; Colitis (immune-mediated) 0.5%

## Notes

- Triple-negative breast cancer: the IMpassion130 threshold was SP142 IC 1% or more (46.4% of samples), not transferable to 22C3 or SP263 (Rugo 2021); the US indication was withdrawn in 2021 and the European one remains.
- Triple-negative breast cancer: the US indication was withdrawn in 2021 but the EU licence and the NICE recommendation (TA639) stand, so in England atezolizumab with nab-paclitaxel remains a commissioned first-line option for PD-L1 immune-cell-positive disease, and NICE TA801 restricts pembrolizumab to the complementary group (CPS 10 or more with immune-cell staining below 1 percent). In early disease three neoadjuvant or adjuvant phase 3 trials were negative or null (NeoTRIP pathological complete response, GeparDouze event-free survival, ALEXANDRA/IMpassion030 invasive disease-free survival) and the NICE appraisals of atezolizumab for early triple-negative disease (GID-TA10531, GID-TA11165) and with paclitaxel for advanced disease (GID-TA10570) were discontinued.
- Colorectal cancer biomarkers: IMblaze370 capped microsatellite instability-high enrolment at 5%, so it is the clean test of checkpoint blockade in microsatellite-stable disease, and it failed: median overall survival 8.87 months with cobimetinib and 7.10 alone against 8.51 with regorafenib (Eng 2019).

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Atezolizumab
- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Atezolizumab
- NICE TA639: atezolizumab with nab-paclitaxel for untreated PD-L1-positive advanced triple-negative breast cancer (1 July 2020): https://www.nice.org.uk/guidance/ta639
- Tecentriq label (openFDA): indications list, no breast cancer indication after the 2021 withdrawal: https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22TECENTRIQ%22
- EMA Tecentriq product page: EU TNBC indication retained: https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq
- NICE TA520: atezolizumab for locally advanced or metastatic non-small-cell lung cancer after chemotherapy: https://www.nice.org.uk/guidance/ta520
- NICE TA584: atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer: https://www.nice.org.uk/guidance/ta584
- NICE TA638: atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer: https://www.nice.org.uk/guidance/ta638
- NICE TA705: atezolizumab monotherapy for untreated advanced non-small-cell lung cancer: https://www.nice.org.uk/guidance/ta705
- NICE TA1071: atezolizumab for adjuvant treatment of resected non-small-cell lung cancer: https://www.nice.org.uk/guidance/ta1071

## Connected records

- biomarkers: [ctDNA MRD positivity (molecular residual disease after curative treatment)](https://onco.cc/biomarkers/ctdna-mrd-positive/), [PD-L1 IC score (immune-cell score, SP142)](https://onco.cc/biomarkers/pd-l1-ic-score/), [PD-L1 TC score (tumour-cell score, SP263 and 28-8)](https://onco.cc/biomarkers/pd-l1-tc-score/)
- cancers: [Advanced hepatocellular carcinoma (BCLC C)](https://onco.cc/cancers/hcc-advanced/), [Alveolar soft part sarcoma](https://onco.cc/cancers/alveolar-soft-part-sarcoma/), [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [BRAF V600-mutant melanoma](https://onco.cc/cancers/braf-v600-melanoma/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Early hepatocellular carcinoma (BCLC 0 and A)](https://onco.cc/cancers/hcc-early/), [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/), [Extrapulmonary neuroendocrine carcinoma](https://onco.cc/cancers/extrapulmonary-nec/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Intermediate hepatocellular carcinoma (BCLC B)](https://onco.cc/cancers/hcc-intermediate/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [PD-L1-high non-small-cell lung cancer without a driver mutation](https://onco.cc/cancers/pdl1-high-nsclc/), [Recurrent or metastatic cervical cancer](https://onco.cc/cancers/recurrent-metastatic-cervical-cancer/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/), [Small cell neuroendocrine carcinoma of the cervix](https://onco.cc/cancers/cervical-small-cell-neuroendocrine-carcinoma/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Immune endocrine damage is usually permanent, and almost nobody is told](https://onco.cc/technologies/rejuv-recovery-endocrine-permanence/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- targets: [PD-L1](https://onco.cc/targets/pdl1/)
- companies: [Chugai Pharmaceutical](https://onco.cc/companies/chugai/), [ETOP IBCSG Partners Foundation](https://onco.cc/companies/etop-ibcsg/), [Roche / Genentech](https://onco.cc/companies/roche-genentech/)
- trials: [A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)](https://onco.cc/trials/nct07227597/), [A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies](https://onco.cc/trials/nct00781612/), [A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocell](https://onco.cc/trials/nct05904886/), [A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr](https://onco.cc/trials/nct06096779/), [A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer](https://onco.cc/trials/nct05645692/), [A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy](https://onco.cc/trials/nct04873362/), [A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors](https://onco.cc/trials/nct04931342/), [A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li](https://onco.cc/trials/nct04524871/), [A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer](https://onco.cc/trials/nct03424005/), [A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab](https://onco.cc/trials/nct07280377/), [A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)](https://onco.cc/trials/nct03148418/), [A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)](https://onco.cc/trials/nct04471727/), [A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab](https://onco.cc/trials/nct05142696/), [A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05047250/), [A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05009069/), [A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer](https://onco.cc/trials/nct07654400/), [A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)](https://onco.cc/trials/nct05859217/), [A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors](https://onco.cc/trials/nct04440735/), [A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-](https://onco.cc/trials/nct06362252/), [A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct04302025/), [A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)](https://onco.cc/trials/nct05652686/), [A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma](https://onco.cc/trials/nct04712643/), [A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC](https://onco.cc/trials/nct05968326/), [A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma](https://onco.cc/trials/nct05440708/), [A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07407933/), [A Study of YL201 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05434234/), [A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct03178552/), [A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus St](https://onco.cc/trials/nct07155174/), [A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.](https://onco.cc/trials/nct07235293/), [ALEXANDRA / IMpassion030](https://onco.cc/trials/impassion030/), [An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)](https://onco.cc/trials/nct05112965/), [An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma](https://onco.cc/trials/nct03533283/), [Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)](https://onco.cc/trials/nct04434040/), [Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients](https://onco.cc/trials/nct06690840/), [Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).](https://onco.cc/trials/nct06663098/), [Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy](https://onco.cc/trials/nct03977194/), [Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types](https://onco.cc/trials/nct05000294/), [ATOMIC (Alliance A021502)](https://onco.cc/trials/atomic/), [Autogene cevumeran phase 1 in resected pancreatic cancer (Memorial Sloan Kettering)](https://onco.cc/trials/autogene-cevumeran-phase-1/), [BARBICAN](https://onco.cc/trials/barbican/), [Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati](https://onco.cc/trials/nct07195695/), [BEAT-meso (ETOP 13-18)](https://onco.cc/trials/beat-meso/), [BEATcc / ENGOT-Cx10 / GOG-3030](https://onco.cc/trials/beatcc/), [BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)](https://onco.cc/trials/nct07625644/), [Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets](https://onco.cc/trials/nct05317858/), [Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer](https://onco.cc/trials/nct06632327/), [CONTACT-03](https://onco.cc/trials/contact-03/), [CUPISCO](https://onco.cc/trials/cupisco/), [DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment](https://onco.cc/trials/nct07472517/), [DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers](https://onco.cc/trials/nct07707895/), [DETERMINE](https://onco.cc/trials/determine-trial/), [DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Mi](https://onco.cc/trials/nct05770102/), [Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL ](https://onco.cc/trials/nct06463665/), [Evaluating Novel Therapies in ctDNA Positive GI Cancers](https://onco.cc/trials/nct05482516/), [FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.](https://onco.cc/trials/nct06733038/), [GeparDouze / NSABP B-59](https://onco.cc/trials/gepardouze/), [IMbassador250](https://onco.cc/trials/imbassador250/), [IMblaze370](https://onco.cc/trials/imblaze370/), [IMbrave050](https://onco.cc/trials/imbrave050/), [IMbrave150](https://onco.cc/trials/imbrave150/), [IMforte](https://onco.cc/trials/imforte/), [IMpassion031](https://onco.cc/trials/impassion031/), [IMpassion130](https://onco.cc/trials/impassion130/), [IMpassion131](https://onco.cc/trials/impassion131/), [IMpower110](https://onco.cc/trials/impower110/), [IMpower133](https://onco.cc/trials/impower133/), [IMpower150](https://onco.cc/trials/impower150/), [IMspire150](https://onco.cc/trials/imspire150/), [IMvigor011](https://onco.cc/trials/imvigor011/), [Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity](https://onco.cc/trials/nct04273061/), [Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study](https://onco.cc/trials/nct07620574/), [MyPathway](https://onco.cc/trials/mypathway/), [NeoTRIP (NeoTRIPaPDL1)](https://onco.cc/trials/neotrip/), [NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial](https://onco.cc/trials/nct06342037/), [OAK](https://onco.cc/trials/oak/), [Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)](https://onco.cc/trials/nct05224141/), [Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation](https://onco.cc/trials/nct06110572/), [Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma](https://onco.cc/trials/nct06921785/), [Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients](https://onco.cc/trials/nct05703971/), [QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors](https://onco.cc/trials/nct03228667/), [Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer](https://onco.cc/trials/nct06712355/), [Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer](https://onco.cc/trials/nct05501665/), [Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer](https://onco.cc/trials/nct04665856/), [Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC](https://onco.cc/trials/nct04446117/), [Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece](https://onco.cc/trials/nct03755791/), [Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC](https://onco.cc/trials/nct05733598/), [Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer](https://onco.cc/trials/nct07339059/), [Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer](https://onco.cc/trials/nct05425940/), [Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [](https://onco.cc/trials/nct02486718/), [SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer](https://onco.cc/trials/nct07322341/), [Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer](https://onco.cc/trials/nct04919382/), [Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated](https://onco.cc/trials/nct06908993/), [Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer](https://onco.cc/trials/nct04941287/), [Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lun](https://onco.cc/trials/nct03811002/), [Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study](https://onco.cc/trials/nct02997228/), [Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer](https://onco.cc/trials/nct04214262/), [Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial](https://onco.cc/trials/nct07388524/), [To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC](https://onco.cc/trials/nct05468489/), [Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based T](https://onco.cc/trials/nct04691817/), [Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study](https://onco.cc/trials/nct04589845/), [Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer](https://onco.cc/trials/nct04373369/)
- key papers: [Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010)](https://onco.cc/key-papers/paper-felip-impower010-adjuvant-atezolizumab-lancet-2021/), [ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors](https://onco.cc/key-papers/paper-asco-irae-guideline-jco-2021/), [Atezolizumab for advanced alveolar soft part sarcoma](https://onco.cc/key-papers/paper-atezolizumab-alveolar-soft-part-sarcoma-chen-nejm-2023/), [Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC](https://onco.cc/key-papers/paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020/), [Atezolizumab plus bevacizumab in advanced malignant peritoneal mesothelioma](https://onco.cc/key-papers/paper-raghav-atezolizumab-bevacizumab-peritoneal-mesothelioma-cancer-discov-2021/), [Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370)](https://onco.cc/key-papers/paper-eng-imblaze370-atezolizumab-cobimetinib-colorectal-lancet-oncol-2019/), [Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab](https://onco.cc/key-papers/paper-gandara-blood-tmb-atezolizumab-nat-med-2018/), [Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN)](https://onco.cc/key-papers/paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019/), [IMbrave050: adjuvant atezolizumab plus bevacizumab versus active surveillance after resection or ablation of high-risk hepatocellular carcinoma](https://onco.cc/key-papers/paper-imbrave050-lancet-2023/), [IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer](https://onco.cc/key-papers/paper-imbrave150-nejm-2020/), [IMvigor011: using a blood test for leftover cancer to decide who gets immunotherapy after bladder surgery](https://onco.cc/key-papers/paper-imvigor011-nejm-2025/), [Iwai and Honjo: tumours use PD-L1 to escape T cells, and blocking it restores attack](https://onco.cc/key-papers/paper-iwai-pdl1-tumour-escape-pnas-2002/), [PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer](https://onco.cc/key-papers/paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021/), [RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer](https://onco.cc/key-papers/paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025/), [Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer](https://onco.cc/key-papers/paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023/), [Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer](https://onco.cc/key-papers/paper-topalian-anti-pd1-nejm-2012/)
- pairings: [Caution: bevacizumab-based regimens with untreated varices](https://onco.cc/pairings/io-varices-caution/), [Caution: PD-1 rechallenge after progression on immunotherapy (RCC)](https://onco.cc/pairings/io-rechallenge-caution-rcc/), [Chemo-immunotherapy induction → maintenance intensification (SCLC)](https://onco.cc/pairings/chemo-io-then-maintenance-sclc/), [ctDNA MRD → adjuvant therapy decision](https://onco.cc/pairings/ctdna-mrd-to-adjuvant/), [Neoadjuvant checkpoint inhibitor → surgery (or no surgery) in dMMR colorectal cancer](https://onco.cc/pairings/neoadjuvant-io-dmmr/), [PD-1 blockade + VEGF inhibition](https://onco.cc/pairings/io-plus-vegf/)
- ideas: [Extended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable](https://onco.cc/ideas/idea-tr1-extended-interval-checkpoint-dosing/), [Give subcutaneous immunotherapy in community clinics and at home](https://onco.cc/ideas/idea-cost-subcutaneous-community/), [Immunotherapy downstaging to transplant with a safe washout](https://onco.cc/ideas/idea-hcc-io-before-transplant/), [Price a cancer drug by how well it works in each cancer](https://onco.cc/ideas/idea-cost-indication-based-pricing/)
- drugs: [Cediranib](https://onco.cc/drugs/cediranib/), [Cobimetinib](https://onco.cc/drugs/cobimetinib/), [Tiragolumab](https://onco.cc/drugs/tiragolumab/), [VENTANA PD-L1 (SP142) Assay](https://onco.cc/drugs/ventana-pd-l1-sp142/), [VENTANA PD-L1 (SP263) Assay](https://onco.cc/drugs/ventana-pd-l1-sp263/)
- terms: [Immune checkpoint](https://onco.cc/terms/immune-checkpoint/), [Immuno-oncology (IO) and checkpoint blockade](https://onco.cc/terms/immuno-oncology/), [Limited-stage vs extensive-stage (small-cell lung cancer)](https://onco.cc/terms/limited-extensive-stage/), [Lung cancer drugs in England: what NICE has recommended](https://onco.cc/terms/lung-uk-drug-access/), [PD-L1 assay discordance (SP142, SP263 and 22C3 in breast cancer)](https://onco.cc/terms/pd-l1-assay-discordance/), [PD-L1 combined positive score 10 in triple-negative breast cancer](https://onco.cc/terms/pd-l1-cps-10-tnbc/), [Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11](https://onco.cc/terms/sclc-molecular-subtypes/)
- roadmaps: [ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment](https://onco.cc/roadmaps/ctdna-tests/), [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)
- pathways: [Bladder cancer (KEGG map)](https://onco.cc/pathways/bladder-cancer-signalling/), [Hepatocellular carcinoma (KEGG map)](https://onco.cc/pathways/hepatocellular-carcinoma-signalling/), [PD-1 / PD-L1 immune checkpoint & T-cell activation](https://onco.cc/pathways/pd1-checkpoint/), [Small cell lung cancer (KEGG map)](https://onco.cc/pathways/sclc-signalling/), [VEGF angiogenesis](https://onco.cc/pathways/vegf-angiogenesis/)
- people: [Ann-Lii Cheng](https://onco.cc/people/ann-lii-cheng/), [Arjun V. Balar](https://onco.cc/people/arjun-balar/), [Elizabeth A. Mittendorf](https://onco.cc/people/elizabeth-mittendorf/), [Enriqueta Felip](https://onco.cc/people/enriqueta-felip/), [Heather A. Wakelee](https://onco.cc/people/heather-wakelee/), [Ho Yeong Lim](https://onco.cc/people/lim-ho-yeong/), [Jonathan E. Rosenberg](https://onco.cc/people/jonathan-rosenberg/), [Martin Reck](https://onco.cc/people/martin-reck/), [Matthew D. Galsky](https://onco.cc/people/matthew-galsky/), [Peter Schmid](https://onco.cc/people/peter-schmid/), [Richard S. Finn](https://onco.cc/people/richard-finn/), [Roy S. Herbst](https://onco.cc/people/roy-herbst/), [Sumanta K. Pal](https://onco.cc/people/sumanta-pal/), [Thomas Powles](https://onco.cc/people/thomas-powles/)
- bottlenecks: [No one can predict who responds to immunotherapy](https://onco.cc/bottlenecks/b-immunotherapy-response/)
- institutions: [IRCCS Humanitas Research Hospital](https://onco.cc/institutions/humanitas/), [National Taiwan University Hospital](https://onco.cc/institutions/ntuh/)

---
JSON: https://onco.cc/api/v1/entities/atezolizumab.json